NFKB1 and Miyoshi myopathy: Recently, we discovered a new 2-iminobenzimidazole compound, XYA1353 (Fig. 1), which exhibits anti-MM activity both in vitro and in vivo by disrupting the canonical NF-κB signaling pathway through reducing expression of P65/P50 and phosphorylation levels of p-IκBα [36].